Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;33(1):57-64.
doi: 10.1111/cyt.13055. Epub 2021 Sep 18.

State-of-the-art cytology of pleural fluid, focusing on the diagnosis of mesothelioma

Sara E Monaco  1 , Luka Brcic  2 , Sanja Dacic  3
Affiliations
Review

State-of-the-art cytology of pleural fluid, focusing on the diagnosis of mesothelioma

Sara E Monaco et al. Cytopathology. 2022 Jan.

Abstract

Mesothelioma has always been a challenging diagnosis to render in body cavity cytology samples. This review is a timely update on pleural fluid cytology and ancillary studies that should be considered in the diagnosis of mesothelial proliferations, specifically mesotheliomas. Information about new diagnostic approaches and ancillary studies in mesothelioma was obtained from the peer-reviewed literature and the authors' experiences. Although the morphological diagnosis of mesothelioma is fraught with numerous challenges given the overlap with other diagnostic entities, there are a variety of immunohistochemical and fluorescence in situ hybridization studies available to help in determining mesothelial origin and in distinguishing malignant proliferations from the more common benign or reactive mesothelial proliferations. Although ancillary studies can be helpful, there are important pitfalls to be aware of when interpreting these cases, and this review highlights some of the challenges that require caution.

Keywords: FISH; immunohistochemistry; mesothelioma; pleural fluid.

PubMed Disclaimer

References

REFERENCES

    1. Churg A, Colby TV, Cagle P et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol. 2000;24(9):1183-1200.
    1. Husain AN, Colby TV, Ordóñez NG et al. Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2018;142(1):89-108.
    1. Chevrier M, Monaco SE, Jerome JA, Galateau-Salle F, Churg A, Dacic S. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology. Cancer Cytopathol. 2020;128(12):939-947.
    1. Sheffield BS, Hwang HC, Lee AF et al. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol. 2015;39(7):977-982.
    1. Kindler HL, Ismaila N, Armato SG 3rd et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(13):1343-1373.

Substances

LinkOut - more resources